Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024

NCT03090165 is registered in ClinicalTrials.gov with Kari Wisinski as lead sponsor.

NCT NCT03090165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03090165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024
Lead sponsor
Kari Wisinski
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 7, 2018
Completion date
October 31, 2026
Enrollment
37 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer